TuHURA Biosciences Inc
Research TuHURA Biosciences Inc (HURA) on Bullrun: market cap USD 129.91M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHURA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 129.91M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 7.54M
- Free cash flow-USD 4.46M
Valuation Snapshot
latest market cap is USD 129.91M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 30.05M | -USD 27.71M | n/a | -0.63 | USD 3.62M | USD 700.02K | USD 20.93M |
| FY2024 | USD 0 | -USD 21.68M | -USD 14.79M | n/a | -1.21 | USD 12.66M | USD 7.16M | USD 14.59M |
| FY2023 | USD 0 | -USD 29.32M | -USD 12.03M | n/a | -2.47 | USD 3.67M | n/a | -USD 1.56M |
| FY2022 | n/a | -USD 22.66M | -USD 20.57M | n/a | n/a | USD 11.78M | n/a | USD 11.80M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 129.91M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 45.10M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 173.10M | n/a | n/a | n/a |
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TuHURA Biosciences Inc's market cap?
TuHURA Biosciences Inc's market capitalization is USD 129.91M.
What does TuHURA Biosciences Inc do?
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.